Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2018-10-30 Investor Presentation
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Presentation for AusBiotech 2018 20 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 31 October 2018 from Regeneus Ltd about the CEO presenting at the AusBiotech 2018 conference. The content includes a detailed investor presentation focusing on the company's regenerative medicine technology, clinical trial data, market strategy, and industry context. It contains forward-looking statements, product descriptions, clinical trial results, and strategic information. There are no financial statements, earnings highlights, or regulatory certifications. The document is a detailed presentation aimed at investors and stakeholders, typical of an Investor Presentation (IP). It is not an Annual Report, Earnings Release, or Regulatory Filing. The length (15,000 characters) and detailed content support this classification.
2018-10-30 English
Appendix 4C - Quarterly 6 pages 238.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly results for the period ended 30 September 2018' and includes an Appendix 4C - Quarterly Cash Flows Statement, which is a standard quarterly report format required by the ASX Listing Rules (specifically Listing Rule 4.7B). The document contains detailed cash flow statements for the quarter, including operating, investing, and financing activities, as well as notes and compliance statements. It provides substantive financial data and analysis for a period shorter than a full fiscal year (a quarter). It is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2018-10-23 English
Re-Released - Appendix 4C - Quarterly 6 pages 238.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly results for the period ended 30 September 2018" and includes an Appendix 4C Quarterly Cash Flows Statement, which is a standard quarterly report format required by the ASX Listing Rules (specifically Listing Rule 4.7B). The document contains detailed cash flow statements for the quarter, including operating, investing, and financing activities, as well as notes and compliance statements. It provides substantive financial data for a period shorter than a full fiscal year (a quarter). There is no indication that this is an announcement of a report or a certification letter; it contains actual financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2018-10-23 English
Notice of Annual General Meeting / Proxy Form 13 pages 875.1KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting 22 November 2018 and Explanatory Statement' and includes details about the AGM such as date, time, location, resolutions to be voted on, voting procedures, and explanatory notes for each resolution. It references the financial report for the year ended 30 June 2018 but does not contain the financial report itself. The document is a notice and explanatory statement for the AGM, which is typical for materials shared with shareholders prior to or at the AGM. It includes agenda items like adoption of the remuneration report, re-election of directors, and approval of placement capacity, all common AGM topics. The document length is about 15,000 characters, which is consistent with a detailed AGM notice and explanatory statement. Therefore, this document fits the category of AGM Information (AGM-R) rather than an Annual Report or other filing type.
2018-10-18 English
Progenza patent to grant in Europe 2 pages 92.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 October 2018 regarding the European Patent Office issuing a Notice of Intention to Grant a patent for the company's product Progenza. The content focuses on intellectual property rights, patent coverage, and commercial protection in various markets. There is no financial data, earnings information, management changes, or regulatory filings related to financial performance. The document is a formal announcement of a patent grant intention, which fits best under a general regulatory announcement category rather than a financial report or management disclosure. It is not a report publication announcement since it does not mention the release of a report, nor is it a certification or legal proceeding update. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-10-17 English
Appendix 3Y Change of Director's Interest Notice 4 pages 302.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed disclosures about changes in securities holdings by company directors, including lapses of unlisted options and shareholdings before and after the change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory filing related to insider transactions. The content focuses on directors' personal share transactions rather than company-wide financial results or management changes. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a certification but a full notice of director dealings.
2018-09-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.